Liquid Biopsy in Cancer Patients: The Hand Lens for Tumor Evolution (Current Clinical Pathology)

Rs. 31,350
  • Edited by: Antonio Russo, Antonio Giordano, Christian Rolfo
  • ISBN: 9783319556598
  • Publisher: Springer Publishing Company
  • Publication Date: August 11, 2017
  • Format: Hardback – 225 pages
  • Language: English
Add to wishlist

SKU 9783319556598 Category Tag

Share
Description

This text is designed to provide readers with a useful and comprehensive resource and state-of-the-art overview about the new, growing and fast-expanding field of “liquid biopsy” for the management of cancer patients. The liquid biopsy represents an important turning point in oncology since it provides a tool for a serial monitoring of disease. Liquid biopsy is our “hand lens” to follow molecular changes that characterize tumor development and progression. The book provide a unique and valuable resource on the clinical relevance of liquid biopsy as well as on the technical aspects of liquid biopsy analysis. All invited authors are recognized experts in their field.  Liquid Biopsy in Cancer Patients: The Hand Lens for Tumor Evolution is targeted to resident and fellows physicians, medical oncologists, molecular biologists and biotechnologists.

Table of Contents
  1. Liquid Biopsy in Cancer Patients: The Hand Lens to Investigate Tumor Evolution
  2. Introduction
  3. References
  4. Precision Oncology: Present Status and Perspectives
  5. Introduction
  6. Current Status: The Case of Colorectal Cancer (CRC)
  7. Future Perspective: Molecular Landscape of Colorectal Cancer
  8. Genomic Classificationof Colorectal Cancer
  9. Pharmacogenomicsand Irinogenomics
  10. Future Perspectives: Precision Medicine Based on Integrative Genomics
  11. Conclusions
  12. References
  13. Cancer Clonal Evolution and Intra-­tumor Heterogeneity
  14. Introduction
  15. Cancer Clonal Evolution
  16. Intra-tumor Heterogeneity
  17. Models of Intra-tumor Heterogeneity: Melanoma and NSCLC
  18. Conclusions and Futures Perspective
  19. References
  20. Tissue Versus Liquid Biopsy: Opposite or Complementary?
  21. References
  22. Technical Aspects for the Evaluation of Circulating Tumor Cells (CTCs)
  23. References
  24. Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DN
  25. Circulating Tumor DNA (ctDNA)
  26. Circulating MicroRNA
  27. References
  28. Technical Aspects for the Evaluation of Exosomes and Their Content
  29. Introduction and Exosome as Biomarkers in Liquid Biopsies
  30. Isolation Methods
  31. Content Characterization
  32. Exosomal miRNAs
  33. Exosomal Proteins
  34. References
  35. Actionable Molecular Targets in Cancer Liquid Biopsy
  36. References
  37. Liquid Biopsy in Breast Cancer
  38. Introduction
  39. Reading the Breast Cancer Genome: An Explosion of Biomarker Diversity
  40. Circulating Tumor DNA (ctDNA)
  41. Minimal Residual Disease (MRD)
  42. Circulating Tumor Cells (CTCs)
  43. References
  44. Liquid Biopsy in Gynecological Cancers
  45. Introduction
  46. Vulvar Cancer
  47. Vaginal Cancer
  48. Cervical Cancer
  49. Liquid Biopsy in Cervical Cancer
  50. Endometrial Cancer
  51. Ovarian Cancer
  52. Circulating Tumor Cells (CTC) in EOC
  53. Prognostic and Predictive Value
  54. Circulating Tumor DNA (ctDNA) in EOC
  55. Exosome and Circulating miRNA in EOC
  56. References
  57. Liquid Biopsy in Prostate Cancer
  58. Introduction
  59. Circulating Tumor Cells (CTCs)
  60. Circulating Tumor DNA (ctDNA)
  61. Exosomes and MicroRNAs (miRNAs)
  62. References
  63. Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC)
  64. Current Status of Lung Cancer
  65. The Importance of Liquid Biopsy in NSCLC
  66. Liquid Biopsy in Non-small Cell Lung Cancer
  67. Circulating Tumor Cells (CTCs)
  68. Circulating Tumor DNA (ctDNA)
  69. Diagnostic Role of ctDNA
  70. Prognostic Role of ctDNA
  71. ctDNA Value in Real-Time Monitoring of the Disease
  72. Exosomes
  73. How the Future of Liquid Biopsy Looks Like: Platelets as a Source of Tumor-RNA
  74. Conclusions
  75. References
  76. Liquid Biopsy in Colorectal Cancer
  77. Introduction
  78. Circulating Tumor Cells (CTCs)
  79. Circulating Tumor DNA (ctDNA)
  80. Exosomes and microRNAs (MiRNAs)
  81. References
  82. Diagnostic and Prognostic Performance of Liquid Biopsy in Hepatocellular Carcinoma
  83. Introduction
  84. Liquid Biopsy as a Potential Diagnostic Tool in HCC
  85. Circulating Tumor Cells (CTCs)
  86. Circulating DNA (ctDNA)
  87. Circulating-Free RNA (cfRNA)
  88. The Prognostic and Predictive Performance of Liquid Biopsy in HCC
  89. Circulating Tumor Cells (CTCs)
  90. Circulating DNA (ctDNA)
  91. Circulating-Free RNA (cfRNA)
  92. Conclusion
  93. References
  94. Liquid Biopsy in Esophageal, Gastric, and Pancreatic Cancers
  95. Esophageal Cancer
  96. CTCs in Esophageal Cancer
  97. ctDNA in Esophageal Cancer
  98. Circulating miRNA and Exosomes in Esophageal Cancer
  99. Gastric Cancer
  100. Circulating Tumor Cells (CTCs) in GC
  101. Circulating-Free Nucleic Acids (cfNAs) in GC
  102. Long Noncoding RNA (lncRNA) in GC
  103. Pancreatic Cancer
  104. Liquid Biopsy in Pancreatic Cancer
  105. Circulating Tumor Cells (CTCs)
  106. Circulating Tumor DNA (ctDNA)
  107. Exosomes
  108. References
  109. Liquid Biopsy in Gastrointestinal Stromal Tumor
  110. Introduction
  111. Clinical, Pathological, and Molecular Features
  112. Circulating Tumor Cells and Circulating Tumor DNA in GIST
  113. Potential Use of Circulating microRNAs as a Liquid Biopsy for GIST Patients
  114. Long Noncoding RNAs (lncRNAs) in GIST
  115. References
  116. Liquid Biopsies in Malignant Melanoma: From Bench to Bedside
  117. Epidemiology and Molecular Biology of Malignant Melanoma
  118. Epidemiology and Molecular Biology of Malignant Melanoma
  119. Molecular Biology
  120. MAPK Pathway
  121. PI3K/AKT Pathway
  122. p16(INK4a)-Rb Pathway
  123. The Role of c-Kit
  124. Immunotherapy
  125. Conclusions
  126. Clinical Management of Advanced Malignant Melanoma
  127. Introduction
  128. Clinical Management
  129. Chemotherapy
  130. Target Therapy
  131. BRAF Inhibitors
  132. Vemurafenib
  133. Dabrafenib
  134. Resistance to BRAF Inhibitors
  135. MEK Inhibitors
  136. Trametinib
  137. Combined BRAF and MEK Inhibitors
  138. Immunotherapy
  139. Anti-CTLA-4 Agents
  140. Anti-PD-1 Agents
  141. Pembrolizumab
  142. Nivolumab
  143. Predictive Biomarkers of Response to Immunotherapy
  144. Combined Immunotherapy
  145. Ipilimumab Plus Nivolumab
  146. Clinical Need of Liquid Biopsies in Malignant Melanoma
  147. Exosomes and miRNAs
  148. Exosomes
  149. Exosomes Biogenesis and Characteristics
  150. Exosomes Isolation
  151. Exosomes in Cancer
  152. Exosomes in Melanoma
  153. miRNAs
  154. miRNA Biogenesis and Incorporation into Exosomes
  155. miRNA Quantification
  156. miRNAs in Cancer
  157. miRNAs in Melanoma
  158. Circulating DNA
  159. Circulating Nucleic Acids as Biomarkers
  160. The Nature of Cell-Free Circulating DNA
  161. Cell-Free DNA Isolation and Analysis
  162. Clinical Utility of Cell-Free DNA in Melanoma
  163. Detection of Cell-Free BRAF Mutation in the Blood
  164. Other Cell-Free DNA Tumour Analysis
  165. Circulating Tumour Cells
  166. Methods for CTC Enrichment and Detection in Melanoma
  167. Target Genes in Melanoma CTC Detection
  168. Clinical Utility of CTC in Melanoma
  169. Challenges and Clinical Implementation
  170. Future Perspectives and Conclusions
  171. References
  172. Liquid Biopsies in Head and Neck Cancer Patients
  173. Background
  174. Circulating Tumour Cells (CTCs) and Circulating Tumour DNA (ctDNA)
  175. CTCs and ctDNA in HNSCC
  176. Exosomes, Microvesicles and miRNAs
  177. Exosomal miRNAs in HNSCC
  178. Conclusions
  179. References
  180. Clinical Practice Implications: Monitoring Drug Response and Resistance
  181. References
  182. Erratum to: Liquid Biopsy in Cancer Patients: The Hand Lens for Tumor Evolution
  183. Index

 

Additional information
Weight1.047 kg
Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.